Skip to main content

Engineering AAV vectors for enhanced safety profiles

 Engineering AAV vectors for enhanced safety profiles involves multiple strategies at both the vector genome and capsid levels. Here is a breakdown of these strategies:



Vector Genome Level:

  • Modifying Vector Genome Sequences: Scientists modify AAV vector genomes by adding, mutating, or deleting specific sequences. For example, self-complementary AAV (scAAV) vectors are designed by deleting key signals from the second inverted terminal repeat (ITR), allowing for more efficient genome replication.
  • Codon Optimization: Optimizing the codon usage of the transgene can enhance its expression efficiency.
  • Promoter and PolyA Sequence Selection: Careful selection and manipulation of promoter and polyadenylation (polyA) sequences can influence transgene expression and tissue specificity.


Capsid Engineering:

Capsid engineering strategies can be categorized into four main categories:

  • Directed Evolution: This approach involves creating capsid mutant libraries using error-prone PCR or introducing peptides with known or speculated affinities into the capsid. It relies on selecting capsids that exhibit desired properties.
  • Rational Design: Scientists use knowledge of capsid structure and function to make precise modifications to improve capsid properties. This approach is guided by insights from structural studies.
  • Computer-Guided Design: Computational modeling and simulations help predict how specific capsid modifications may affect interactions with host cells and the immune system.
  • Combinations: Combining different strategies, such as directed evolution and rational design, can optimize capsids for specific purposes.


Circumventing Immune Responses:

AAV vectors, despite low immunogenicity, can still trigger immune responses that affect safety. Strategies to address these issues include:

  1. CpG Motif Modification: Unmethylated CpG motifs in AAV vectors can activate immune responses. Modifying the vector's genome to reduce CpG motifs can mitigate this risk.
  2. Innate Immunity Sensors: Understanding how AAV vectors interact with innate immunity sensors like TLR9 and MDA5 can help design vectors that minimize immune activation.
  3. Neutralizing Antibody Escape: Some strategies focus on escaping neutralizing antibodies (NAbs) to maintain vector efficacy. Directed evolution and rational design can generate AAV variants that are less susceptible to NAbs.
  4. Complement Activation: Complement activation can pose risks. Capsid engineering approaches aim to understand and modify AAV capsids to reduce complement activation, especially in the alternative pathway.


Minimizing Genotoxicity:

  • Integration Control: While AAV vectors typically do not integrate into the host genome, there is a low risk of genotoxicity. Scientists explore methods to control integration, including using homology arms for targeted integration and CRISPR-Cas9 combinations.
  • Partial Genomes: Strategies are devised to prevent the generation of partial genomes, which may lead to genotoxicity. Inverted genomes for self-complementary AAVs and deleting promoter-proximal D-sequences for single-stranded AAVs are considered.
  • Promoter and Enhancer Selection: The choice of promoters and enhancers can affect the risk of genotoxicity. Some regulatory elements may lead to overexpression or oncogenicity, while others can be used to limit transgene expression to safe levels.


Controlling On-Target Delivery and Off-Target Expression:

  • Tissue-Specific Promoters: Using tissue-specific promoters or regulatory elements ensures that gene expression is limited to the target tissue, reducing off-target effects.
  • Clonal Selection: Clonal selection techniques help identify AAV clones that exhibit the highest transduction efficiency in the target tissue while minimizing off-target transduction.
  • Balancing Safety and Efficacy: Striking the right balance between transduction efficiency and safety is crucial, especially when using high vector doses or systemic delivery.


In summary, engineering AAV vectors for improved safety profiles involves a multifaceted approach that encompasses vector genome modifications, capsid engineering, immune response mitigation, genotoxicity control, and precise control over on-target and off-target transduction. These strategies aim to enhance the safety and efficacy of AAV-based gene therapies.


For details

https://www.frontiersin.org/articles/10.3389/fmmed.2022.1054069/full

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more

Overview of Cut Point Calculation in the Presence of Pre-existing Antibodies

The process involves statistical methods that account for variations in baseline ADA levels across the study population. Here’s a structured approach to calculate the cut point when there is a pre-existing antibody response: 1. Collect Baseline ADA Samples Sample Population : Collect samples from a representative population of treatment-naïve subjects (typically 50-100 individuals). These baseline samples should reflect the typical range of pre-existing ADA levels within the target patient population. Matrix Type : Use serum or plasma samples, as appropriate for the assay matrix. Time Points : Ideally, collect multiple samples per subject pre-treatment to get a clear baseline. 2. Run Baseline Samples in ADA Assay Perform the ADA assay on all baseline samples, running each sample in triplicate to account for intra-assay variability. Record the response values (e.g., optical density (OD) in ELISA) for each sample. If using multiple replicates, calculate the mean response for each sample....
Read more